KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Kala Pharmaceuticals, Inc.

490 Arsenal Way
Suite 120
Watertown, MA 02472
United States
781-996-5252
http://www.kalarx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees130

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark T. IwickiChairman, Pres & CEO927.39kN/A1966
Mr. Eric L. TrachtenbergGen. Counsel, Chief Compliance Officer & Corp. Sec.703.39kN/A1973
Dr. Kim BrazzellChief Medical Officer643.9kN/A1953
Dr. Justin HanesFounder & Chair of the Scientific Advisory BoardN/AN/AN/A
Ms. Mary Reumuth CPA, CPACFO & TreasurerN/AN/A1975
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Kala Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.